Kazia Therapeutics Limited (KZIA)
Chart Events
Performance Outlook
| Previous Close | 1.8000 |
| Open | 1.7900 |
| Bid | 1.6900 x 2200 |
| Ask | 1.7100 x 800 |
| Day's Range | 1.6800 - 1.8300 |
| 52 Week Range | 1.6300 - 12.2800 |
| Volume | |
| Avg. Volume | 625,143 |
| Market Cap | 23.383M |
| Beta (5Y Monthly) | 2.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.30 |
- Benzinga
Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the presentation of new data from an ongoing phase 1 trial of paxalisib in combination with radiotherapy for brain metastases. Interim data from the first stage of the study reports that all nine evaluable patients experienced a complete or partial response, representing an overall response rate (ORR) of 100%. A typical ORR associated with whole brain radiotherapy alone can commonly range from 20-45% in published studies. Also Read: Kazia Share
- PR Newswire
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of promising new data from an ongoing phase I clinical trial of paxalisib in combination with radiotherapy for the treatment of brain metastases, sponsored by Memorial Sloan Kettering Cancer Center in New York, NY.
- Benzinga
Kazia Shares Tumble After Update From Pivotal Brain Tumor Trial
Kazia Therapeutics Limited (NASDAQ: KZIA) said GBM AGILE, a pivotal study for paxalisib in newly diagnosed glioblastoma, did not meet pre-defined criteria for continuing to a second stage. Patients enrolled in the first stage of the paxalisib arm will continue on treatment as per protocol, and in follow-up, until completion of the final analysis, which Kazia anticipates receiving in 2H of 2023. Given that recruitment is complete, the study will not open to the paxalisib arm in Germany or China.
